Supplementary Figure 4 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
| Autor: | José Baselga, Scot Ebbinghaus, Yang Song, Ann Leighton-Swayze, Richard A. Klinghoffer, Jason Frazier, Youyuan Xu, Sharda Jha, Christopher G. Winter, Theresa Zhang, Brian B. Haines, Desamparados Roda, Irene Braña, Mark N. Stein, Andrés Cervantes, Johanna C. Bendell, Sriram Sathyanarayanan, Serena Di Cosimo |
|---|---|
| Rok vydání: | 2023 |
| Popis: | Supplementary Figure 4. Responder biomarker hypothesis for ridaforolimus and dalotuzumab?based therapy |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|